The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 1 of 36
Back to Result List

The grapevine-shoot extract Vineatrol30 Inhibits the chemically induced malignant transformation of BALB/c-3T3 Cells

  • Vineatrol (R) 30 (developed and produced jointly by Breko GmbH [Bremen, Germany] and Actichem [Montauban, France]) is a grapevine-shoot extract that contains resveratrol as well as considerable amounts of resveratrol oligomers. In the present study it is shown that Vineatrol30 at a noncytotoxic concentration of 2.3 mu g/mL significantly reduced the number of malignantly transformed foci induced by a sequential treatment of BALB/c-3T3 cells with 3-methylcholanthrene and 12-O-tetradecanoylphorbol 13-acetate in the so-called BALB/c-3T3 cell transformation assay. At a higher concentration Vineatrol30 drastically decreased the relative plating efficiency of the cells. Furthermore, the results suggest that the resveratrol oligomers present in Vineatrol30, independently from resveratrol itself, were indeed able to inhibit the formation of malignantly transformed BALB/c-3T3 foci.

Export metadata

Additional Services

Search Google Scholar Statistics
Metadaten
Author details:Carsten Müller, Kristina Ullmann, Pablo SteinbergORCiDGND
DOI:https://doi.org/10.1089/jmf.2010.0022
ISSN:1096-620X
Title of parent work (English):Journal of medicinal food
Publisher:Liebert
Place of publishing:New Rochelle
Publication type:Article
Language:English
Year of first publication:2011
Publication year:2011
Release date:2017/03/26
Tag:BALB/c-3T3 cells; Vineatrol (R) 30; cell transformation assay; resveratrol; resveratrol oligomers
Volume:14
Issue:1-2
Number of pages:6
First page:34
Last Page:39
Funding institution:Federal Ministry for Education and Research in Germany [0315373C]
Organizational units:Mathematisch-Naturwissenschaftliche Fakultät / Institut für Ernährungswissenschaft
Peer review:Referiert
Accept ✔
This website uses technically necessary session cookies. By continuing to use the website, you agree to this. You can find our privacy policy here.